IgA Nephropathy

Key FDA approvals, pivotal IgAN and glomerular trial results, and transplant and CKD insights from November 2025.

FDA grants accelerated approval for sibeprenlimab for reducing proteinuria in IgA nephropathy.

Pediatric IgA nephropathy shows slow progression, high remission rates, and frequent relapse, with new risk factors identified to improve long-term prognosis and management.

A curated recap of 8 impactful trial updates from the American Society of Nephrology Kidney Week 2025.

Non-RASi antihypertensive use before pregnancy in women with IgAN increased the risk of severe HDP and preterm delivery.

Dual BLyS/APRIL inhibition with telitacicept cut proteinuria and maintained kidney function in adults with IgA nephropathy.

Dual BLyS/APRIL inhibition with telitacicept led to significant 24h-UPCR reductions, lower progression-risk thresholds, and stable eGFR compared with placebo.

Sibeprenlimab shows promising results in reducing proteinuria and improving kidney health in IgA nephropathy.

Jonathan Barratt, MBChB, PhD, discusses 36-week atacicept data from ASN Kidney Week 2025.

Discover groundbreaking insights from the ORIGIN 3 study on IgA nephropathy, showcasing promising results and future treatment possibilities.

Phase 3 trial results reveal atacicept significantly reduces proteinuria in IgA nephropathy, paving the way for potential FDA approval in 2026.

Kidney Week 2025 showcases groundbreaking clinical trials and FDA approvals, marking a transformative era in nephrology and kidney disease treatment.

Elevated neutrophil-to-lymphocyte ratio predicts early kidney decline in IgA nephropathy.

Final results from APPLAUSE-IgAN demonstrate iptacopan’s superiority versus placebo for slowing IgAN progression and will be used to support its full approval.

Radhakrishnan emphasizes the importance of individualized IgAN care and how to best use currently available and emerging treatments.

Increases in short-term kidney function decline were observed following post-COVID-19 vaccination gross hematuria in individuals with IgA nephropathy.

Radhakrishnan breaks down the recent KDIGO IgAN guidelines and describes the evolving therapeutic landscape of IgA nephropathy.

The Q3 recap for nephrology spotlights key FDA decisions, new KDIGO IgA nephropathy guidelines, and other top renal news and research.

Barratt describes the evolving diagnostic and therapeutic landscape of IgAN and breaks down key recommendations from the new KDIGO guidelines.

Check out renal FDA news, new KDIGO guidelines on IgAN and IgAV management, research about hypertensive kidney disease, and more.

Neuen describes varying treatment effects with 4 different classes of IgAN therapeutics and future opportunities for personalized treatment.

Neuen reviews recent advances in IgAN treatment and findings from a systematic review and meta-analysis guiding their use in clinical practice.

The 2025 guideline updates previous recommendations made in the 2021 glomerular disease guideline based on recent therapeutic advances in IgAN.

Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.

The REMS label update reduces the frequency of liver function monitoring and removes the embryo-fetal toxicity monitoring requirement.